Automated Data in ICU Boost VTE Prophylaxis

P a folate analogue metabolic inhibitor, has been approved as the first maintenance treatment for locally advanced or metastatic nonsquamous non–small cell lung cancer, the Food and Drug Administration announced. “This drug represents a new approach in the treatment of advanced non–small cell lung cancer,” Dr. Richard Pazdur, director of the FDA’s office of oncology drug products, said in the statement. “Typically, patients whose tumors respond to chemotherapy do not receive further treatment after four to six chemotherapy cycles,” he added. Dr. Pazdur referred to a study that showed an advantage in overall survival in certain patients who received maintenance therapy with pemetrexed. Maintenance therapy with pemetrexed was compared with placebo in a multicenter study of 663 patients with ACIP Picks Five Priority Groups for H1N1 Vaccination